Kattih et al. additionally demonstrated that mutations in IDH1 and IDH2 are associated with an elevated risk of cardiac dysfunction in patients with acute myeloid leukemia (AML) relative to those with wild-type IDH1 and IDH2. Here, IDH2 is linked to acute myeloid leukemia.